Mesna


Mesna
Systematic (IUPAC) name
sodium 2-sulfanylethanesulfonate
Identifiers
CAS number	19767-45-4
ATC code	V03AF01
PubChem	29769
Chemical data
S₂
mol
Pharmacokinetic data
Bioavailability	45–79% (Oral)
Oxidised in circulation
Half life	0.36–8.3 hours
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	B1 (Au), B (U.S.)
Legal status	S4 (Au), POM (UK), ℞-only (U.S.)
Routes	Oral, intravenous

Mesna (ifosfamide. It is currently marketed by Baxter as Uromitexan® and Mesnex®.

Mesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites such as cysteine.

v • d • e Dimethoxanate

v • d • e Detoxifying agents for Sodium folinate - Rasburicase - Palifermin

Chemotherapeutic adjuvants

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mesna". A list of authors is available in Wikipedia.